Stately Life-Science Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 16 Year, 14 Days
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 59.39%
- Profit Growth 644.62%
- Ebitda 485.27%
- Net Worth 941.28%
- Total Assets 69.72%
About Stately Life-Science
Stately Life-Science Private Limited (SLPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 February 2009 and has a history of 16 years. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Baldeep Dogra and Pradeep Kadam serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100MH2009PTC190199
- Company No.
190199
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Stately Life-Science?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Baldeep Dogra  | Director | 09-Feb-2009 | Current |
| Pradeep Kadam | Director | 29-Jan-2018 | Current |
Financial Performance of Stately Life-Science.
Stately Life-Science Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 59.39% increase. The company also saw a substantial improvement in profitability, with a 644.62% increase in profit. The company's net worth Soared by an impressive increase of 941.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stately Life-Science?
In 2023, Stately Life-Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Swastik Furnaces Private LimitedBaldeep Dogra is a mutual person
Seco Warwick Allied Private LimitedBaldeep Dogra is a mutual person
Stately Healthcare Private LimitedBaldeep Dogra is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stately Life-Science?
Unlock and access historical data on people associated with Stately Life-Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stately Life-Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stately Life-Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
